how does the body make glp 1 GLP-1 Era: Why These Intestinal Peptides Are Reshaping Modern Medicine THE PCCA BLOG | GLP-1:

The central question is no longer just whether a clear statistical link exists, but whether manufacturers and regulators exercised appropriate caution while long-term, real-world data is still developing

The risk ranking showed that Semaglutide q.w (87.1) ranked first, followed by ITCA650 (83.8), Lixisenatide (83.2), Liraglutide (78.1), Taspoglutide (74.1), Efpeglenatide q.m (68.4), Exenatide b.i.d (57.3), oral Semaglutide (55.3), Exenatide q.w (54.9), Efpeglenatide q.w (39.4), and PEX168 (35.8), Placebo (16.5), while PEX168(Loxenatide) had the lowest rate of GI adverse reactions

Because everyone responds differently, setting expectations on GLP-1s means focusing on larger patterns rather than quick results

GLP-1 drugs have been shown to have cardiovascular benefits, such as a reduced risk of heart attacks and strokes in people with type 2 diabetes